Li Peng, Ph.D.
Li Peng has nearly 15 years of industry experience in biologics discovery and development. She oversees antibody discovery and engineering, technology development, immunology, pharmacology and CMC. Li was the driving force behind the development of Palleon’s EAGLE and HYDRA platforms. Prior to joining Palleon, Li worked at Medimmune/AstraZeneca for about 10 years in roles of increasing responsibility leading drug discovery programs and cross-functional project teams. She has published 30 scientific papers and is an inventor on 14 patents and patent applications. Li earned a doctorate in biochemistry and molecular biology from the University of California, Davis.